about
Caffeine: cognitive and physical performance enhancer or psychoactive drug?Ultrasonographic detection and assessment of the severity of Crohn's disease recurrence after ileal resection.Psychopathological features of irritable bowel syndrome patients with and without functional dyspepsia: a cross sectional studyHigh prevalence of symptoms in a severely abused "non-patient" women population.The newer Opioid Agonist Treatment with lower substitutive opiate doses is associated with better toxicology outcome than the older Harm Reduction Treatment.Systematic review of the toxicological and radiological features of body packing.The Clinical and Radiological Examination of Acute Intimate Partner Violence Injuries: A Retrospective Analysis of an Italian Cohort of Women.Alcohol intake and binge drinking among Italian adolescents: The role of drinking motives.Erratum to: Agonist Opioid Treatment as historical comprehensive treatment ('Dole & Nyswander' methodology) is associated with better toxicology outcome than Harm Reduction Treatment.Body Image and Eating Disorders are Common among Professional and Amateur Athletes Using Performance and Image Enhancing Drugs: A Cross-Sectional Study.Is recurrence in major depressive disorder related to bipolarity and mixed features? Results from the BRIDGE-II-Mix study.The Association of Anger with Symptom Subtypes in Severe Obsessive-Compulsive Disorder Outpatients.Fatigue Experiences Among OCD Outpatients.Commentary on confounding definitions and descriptions of body packing.Caffeine-Related Deaths: Manner of Deaths and Categories at Risk.Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life.Systematic Review of Drug Packaging Methods in Body Packing and Pushing: A Need for a New ClassificationPatients’ Expectations for Antidepressant Treatment OutcomeLacosamide in bipolar disorder: A 30-day comparison to a retrospective control group treated with other antiepilepticsBody packing and intra-vaginal body pushing of cocaine: A not-so-rare eventA lethal case of hoarding due to the combination of traumatic and confined space asphyxiaQuetiapine Abuse Fourteen Years Later: Where Are We Now? A Systematic ReviewPharmacotherapy for Hoarding Disorder: How did the Picture Change since its Excision from OCD?Medico-Legal Analysis of Two Recent Cases of Body PackingGhrelin: From a gut hormone to a potential therapeutic target for alcohol use disorderMercuric chloride poisoning: symptoms, analysis, therapies, and autoptic findings. A review of the literaturePlasma Risperidone-related Measures in Children and Adolescents with Oppositional Defiant/Conduct DisordersThe central role of psychopathology and its association with disease severity in inflammatory bowel disease and irritable bowel syndrome
P50
Q28080581-BCDD0F93-927A-4650-9B06-86784AF167BCQ33622831-8AA82707-39C2-41A1-B746-3C32A1739108Q34003818-7B8CA11B-5806-4162-A4B7-A781096733DAQ34576813-7A4F786E-D55F-4ED6-8BA9-E13B29A88DB9Q37442770-15972117-F4B7-4403-94B0-87531AAD82A5Q38757241-FC8D6FA5-8DAD-4DF1-A5CD-6E3680C0FE9FQ40233242-55FF7DC5-4A42-455D-88ED-9AD2E1F2C4A6Q41048168-60046FA3-414A-43BF-AC13-1F7F66A7EFB3Q42322076-A4944C01-BA8A-4D36-85A8-ABAEEF735C01Q43364491-B7B4625E-CC2F-425B-89DC-188E5FB5EE16Q47558098-FE646BA3-7D43-44D2-A463-9F71417607B7Q47575130-C852A035-9FE6-4E47-9BA5-A0A0EB104E07Q48088069-82C30F82-6BC6-4767-86A9-849841027D3EQ50569762-A5AAA4FB-B6D3-446B-80AD-189836BF2454Q55155716-A6669731-9652-41F1-BA20-F67455336181Q55443557-5A3AAC4F-7916-41C3-AEFD-7FF5FB440193Q57282374-DC1425F8-4AFA-4282-AB3B-F8633EECD41DQ60439939-373D1DD3-EC6B-4E7A-8A90-503196BB3684Q60445906-FA28FB07-F0C4-41B3-94ED-6F81F684A38AQ88255784-ECD8096D-C34D-4E62-B25E-70C9183A609CQ90395512-9C7CE276-251A-4A07-8855-A512C9981398Q90408654-77812DC5-603F-4393-A13B-623B237CEBECQ91206670-5FBE3B6F-FC07-4A48-810F-FBA3BF312EDDQ91326874-1CD043FF-57FE-465F-A19E-D49EA29B7149Q91437165-42F54165-E986-4C53-BB40-1594A4916794Q92749215-F345DEA7-B040-44E1-8CCE-AEDB9FECA699Q92775940-DBB802BC-9B7B-401C-AFFE-375394882F01Q93096308-1D7E17AD-16C1-4499-BAE5-08DB57501FA3
P50
description
investigador
@es
researcher
@en
name
Daria Piacentino
@en
type
label
Daria Piacentino
@en
prefLabel
Daria Piacentino
@en
P31
P496
0000-0002-9991-7403